42P - Promoter hypermethylation of BRCA1, DAPK1 and RASSF1A is associated with increase mortality among breast cancer patients

Date 17 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Translational Research
Presenter Prasant Yadav
Citation Annals of Oncology (2016) 27 (suppl_9): ix9-ix18. 10.1093/annonc/mdw574
Authors P. Yadav1, M. Mirza1, K. Nandi1, R.C. Kaza2, S.K. Jain2, A. Saxena1
  • 1Department Of Biochemistry, Maulana Azad Medical College New Delhi A.L.N. Hospital, 110002 - New Delhi/IN
  • 2Department Of Surgery, Maulana Azad Medical College New Delhi A.L.N. Hospital, 110002 - New Delhi/IN



Promoter hypermethylation has been seen in several genes in cancer development and progression. Hypermethylation-derived silencing of different tumor suppressor genes (TSGs) has been observed to be associated with breast cancer pathogenesis. The current study was aimed to evaluate the role of TSGs (BRCA1, DAPK1 and RASSF1A) promoter hyermethylation in breast cancer and their correlation with clinico-pathological features of breast cancer patients.


Promoter hypermethylation status of BRCA1, DAPK1 and RASSF1A was observed in mononuclear cells (MNCs) DNA extracted from peripheral blood samples of 60 histopathologically confirmed newly diagnosed, untreated cases of breast cancer as well as 60 age and sex matched healthy controls by using MS-PCR. Total follow up period was 45 months and mean follow up time was 30.98 months. The association of promoter methylation and breast cancer specific mortality was analyzed by Cox-proportional hazards models. Kaplan-Meier survival analysis was performed for overall survival of breast cancer patients. The study was ethically approved by Institutional Ethics Committee, Maulana Azad Medical College, New Delhi.


A significant association was seen between BRCA1, DAPK1 and RASSF1A promoter hypermethylation (51.66% (P 


Our results suggest that promoter hypermethylation of TSGs may be a potential new biomarker of breast cancer prognosis. A large pool study will be required to confirm these findings.

Clinical trial indentification

Legal entity responsible for the study

Dr. Alapna Saxena, Mr. Prasant Yadav


Maulana Azad Medical College


All authors have declared no conflicts of interest.